These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32663328)

  • 1. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma.
    Dinh TA; Jewell ML; Kanke M; Francisco A; Sritharan R; Turnham RE; Lee S; Kastenhuber ER; Wauthier E; Guy CD; Yeung RS; Lowe SW; Reid LM; Scott JD; Diehl AM; Sethupathy P
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):803-817. PubMed ID: 30763770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique genomic profile of fibrolamellar hepatocellular carcinoma.
    Cornella H; Alsinet C; Sayols S; Zhang Z; Hao K; Cabellos L; Hoshida Y; Villanueva A; Thung S; Ward SC; Rodriguez-Carunchio L; Vila-Casadesús M; Imbeaud S; Lachenmayer A; Quaglia A; Nagorney DM; Minguez B; Carrilho F; Roberts LR; Waxman S; Mazzaferro V; Schwartz M; Esteller M; Heaton ND; Zucman-Rossi J; Llovet JM
    Gastroenterology; 2015 Apr; 148(4):806-18.e10. PubMed ID: 25557953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
    Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
    Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1.
    Shirani M; Levin S; Shebl B; Requena D; Finkelstein TM; Johnson DS; Ng D; Lalazar G; Heissel S; Hojrup P; Molina H; de Jong YP; Rice CM; Singhi AD; Torbenson MS; Coffino P; Lyons B; Simon SM
    Cancer Res; 2024 Aug; 84(16):2626-2644. PubMed ID: 38888469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
    Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
    Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
    Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
    Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
    Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
    Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
    Simon EP; Freije CA; Farber BA; Lalazar G; Darcy DG; Honeyman JN; Chiaroni-Clarke R; Dill BD; Molina H; Bhanot UK; La Quaglia MP; Rosenberg BR; Simon SM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(44):E5916-25. PubMed ID: 26489647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
    Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
    Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
    Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
    Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
    Kim J; Kim Y; Lee B
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
    Honeyman JN; Simon EP; Robine N; Chiaroni-Clarke R; Darcy DG; Lim II; Gleason CE; Murphy JM; Rosenberg BR; Teegan L; Takacs CN; Botero S; Belote R; Germer S; Emde AK; Vacic V; Bhanot U; LaQuaglia MP; Simon SM
    Science; 2014 Feb; 343(6174):1010-4. PubMed ID: 24578576
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
    Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.
    Schalm SS; O'Hearn E; Wilson K; LaBranche TP; Silva G; Zhang Z; DiPietro L; Bifulco N; Woessner R; Stransky N; Sappal D; Campbell R; Lobbardi R; Palmer M; Kim J; Ye C; Dorsch M; Lengauer C; Guzi T; Kadambi V; Garner A; Hoeflich KP
    Gastro Hep Adv; 2023; 2(3):307-321. PubMed ID: 39132655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.